Impact of Ketone Bodies and Epigallocatechin Gallate in Multiple Sclerosis

Treatment tested

• Wax, emulsifying

Placebo or sham

• Placebo

Other measures (27)

Inclusion Criteria: * Multiple Sclerosis patients older than 19 years ans under 65 who sign informed consent of the study Exclusion Criteria: * Patients with coconut oil intolerance or other chronic metabolic pathologies

Based on the fact that the fundamental pathogenic mechanism of the Multiple Sclerosis (MS) disease is neuroinflammation, related in turn to cellular oxidation and mitochondrial alterations, this project aims to assess the impact of a nutritional intervention on the evolution of MS patients in their different slopes. To this end, the administration of medium-chain triglycerides, whose metabolism produces the increase of ketone bodies in the blood, will be carried out; and another of the antioxidant polyphenol epigallocatechin gallate. This procedure will be applied over 6 months, based on a isocaloric Mediterranean diet, with a population for the study of 80 patients with different variants of the disease. The assessment of the intervention will be carried out every two months, at motor-functional, anthropometric, cognitive and emotional, inflammatory, and oxidation levels.